Vivos Therapeutics Statistics
Share Statistics
Vivos Therapeutics has 5.89M
shares outstanding. The number of shares has increased by 73.39%
in one year.
| Shares Outstanding | 5.89M |
| Shares Change (YoY) | 73.39% |
| Shares Change (QoQ) | 21.8% |
| Owned by Institutions (%) | 0.33% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 991 |
| FTD / Avg. Volume | 1.03% |
Short Selling Information
The latest short interest is 259.4K, so 4.4% of the outstanding
shares have been sold short.
| Short Interest | 259.4K |
| Short % of Shares Out | 4.4% |
| Short % of Float | 4.89% |
| Short Ratio (days to cover) | 3.05 |
Valuation Ratios
The PE ratio is -1.93 and the forward
PE ratio is -2.45.
Vivos Therapeutics's PEG ratio is
0.02.
| PE Ratio | -1.93 |
| Forward PE | -2.45 |
| PS Ratio | 1.43 |
| Forward PS | 0.7 |
| PB Ratio | 2.71 |
| P/FCF Ratio | -1.62 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Vivos Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.5,
with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.5 |
| Quick Ratio | 1.5 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $137,899.08 |
| Profits Per Employee | $-102,165.14 |
| Employee Count | 109 |
| Asset Turnover | 0.98 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 16.84% in the
last 52 weeks. The beta is 7.27, so Vivos Therapeutics's
price volatility has been higher than the market average.
| Beta | 7.27 |
| 52-Week Price Change | 16.84% |
| 50-Day Moving Average | 2.69 |
| 200-Day Moving Average | 3.25 |
| Relative Strength Index (RSI) | 41.01 |
| Average Volume (20 Days) | 96,430 |
Income Statement
In the last 12 months, Vivos Therapeutics had revenue of 15.03M
and earned -11.14M
in profits. Earnings per share was -1.68.
| Revenue | 15.03M |
| Gross Profit | 9.02M |
| Operating Income | -11.17M |
| Net Income | -11.14M |
| EBITDA | -10.55M |
| EBIT | -11.17M |
| Earnings Per Share (EPS) | -1.68 |
Full Income StatementBalance Sheet
The company has 6.26M in cash and 1.51M in
debt, giving a net cash position of 4.75M.
| Cash & Cash Equivalents | 6.26M |
| Total Debt | 1.51M |
| Net Cash | 4.75M |
| Retained Earnings | -104.19M |
| Total Assets | 11.28M |
| Working Capital | -1.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -12.69M
and capital expenditures -568K, giving a free cash flow of -13.26M.
| Operating Cash Flow | -12.69M |
| Capital Expenditures | -568K |
| Free Cash Flow | -13.26M |
| FCF Per Share | -2.64 |
Full Cash Flow StatementMargins
Gross margin is 60%, with operating and profit margins of -74.32% and -74.09%.
| Gross Margin | 60% |
| Operating Margin | -74.32% |
| Pretax Margin | -74.09% |
| Profit Margin | -74.09% |
| EBITDA Margin | -70.22% |
| EBIT Margin | -74.32% |
| FCF Margin | -88.21% |
